PVRIG Antibody (2334A) [Janelia Fluor® 549]
Novus Biologicals, part of Bio-Techne | Catalog # FAB93651I
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
Janelia Fluor 549
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # 2334A
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human embryonic kidney cell, HEK293-derived human PVRIG protein
Thr 41 & Glu43-Leu172
Accession # Q6DK17
Thr 41 & Glu43-Leu172
Accession # Q6DK17
Specificity
Detects human PVRIG in direct ELISAs.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for PVRIG Antibody (2334A) [Janelia Fluor® 549]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: PVRIG
Long Name
Poliovirus Receptor Related Immunoglobulin Domain Containing
Alternate Names
C7orf15, CD112R
Additional PVRIG Products
Product Documents for PVRIG Antibody (2334A) [Janelia Fluor® 549]
Product Specific Notices for PVRIG Antibody (2334A) [Janelia Fluor® 549]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...